A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
A phase 2 trial of HLX43 DOSE 1 in nasopharyngeal carcinoma, run by Shanghai Henlius Biotech, now recruiting.
Overview
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy is a phase 2 interventional study registered as NCT06839066 by Shanghai Henlius Biotech, with 70 participants planned, started 2025-04-02 and due to reach its primary completion in 2026-11-22. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2 and HLX43 DOSE 3.
Similar pages
not linked directly; found by shared links- TrialAutologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialPhase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Shares Shanghai Henlius Biotech and the tag pipeline.